Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy.
about
Selective gene silencing by viral delivery of short hairpin RNAThe ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implicationsPotential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse modelsInfection and killing of multiple myeloma by adenovirusesOncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virusSynergistic interaction between oncolytic viruses augments tumor killing.VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia.Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma.Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx.Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene.Curative one-shot systemic virotherapy in murine myeloma.Oncolytic adenoviruses - selective retargeting to tumor cells.Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites.Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation.Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics.Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysisCell carriers to deliver oncolytic viruses to sites of myeloma tumor growth.Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus.Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV.Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.Oncolytic virotherapy for multiple myeloma: past, present, and future.Gene and virotherapy for hematological malignanciesDelayed transmission selects for increased survival of vesicular stomatitis virus.Vesiculovirus neutralization by natural IgM and complement.Antitumor efficacy of oncolytic herpes simplex virus adsorbed onto antigen-specific lymphocytes.Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.Proteomic analyses of gastric cancer cells treated with vesicular stomatitis virus matrix protein.Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cellsPEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.Systemic virotherapy for multiple myeloma.The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers.Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells.Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach.Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors
P2860
Q21245112-FE3083AF-0833-4F4C-BAF2-E22481524936Q27002660-501E816B-21AE-4A94-A661-9489B9362124Q33579385-9F1F02DD-F0EF-4391-B0AA-05A6626BCD41Q33585559-BF3FFF02-6E1F-47D1-9A04-B2478BC88667Q33620680-8A000A65-F4A8-4C7C-9021-BB3E073E8EC5Q33691833-73FE0BE1-5343-4FEB-B19B-4BDED41A4E70Q33895494-5B032B46-B964-4AC5-A079-528CBB8B898FQ33931616-4EB39D2E-AF17-4E9C-BF71-004828C2B8F0Q34382986-CDE0ECF2-FDC0-47B9-8632-24CBAB55C95DQ34613146-C33D69FA-2B7F-414E-B8C1-4FBC0553E061Q35784861-3816911E-2D71-41D1-9C0C-AE7277B27A3CQ36007610-D6667FDB-D32F-4E61-960F-C2811BC89C6CQ36139716-3C14CB7C-5D05-4B9E-9C66-BF9B6C5F97E2Q36318189-13F88CD6-19E6-4A51-A113-47FDA146B8E5Q36574519-6A1B2C3D-34B1-4AE1-BA6E-EF561FEDADF6Q36667968-32C9BD6A-93FA-4CD2-AB27-8D7CBEBA5A57Q36673201-C20E0041-073A-4505-8D51-A76BA4193983Q36793937-F2D92274-F361-4019-A92A-BE1A8B20D641Q36937117-5434127C-E257-4F84-B103-55007C97C4E7Q36984500-52086EA4-B58B-4141-A937-D2AEE3B69A05Q37115384-A1420819-7E5E-4F7B-91C4-B7C282F36CBDQ37311960-1D02D5EA-C401-492A-8EF8-D043852386B5Q37373616-2C1C9962-B909-4130-A29D-3BDE74A845B6Q37381298-92A9C232-9AE1-417D-9A7F-23E3B725E7A9Q37602550-99A7396B-BD2C-4355-A722-D6B7A6B0B830Q38803056-3908D620-C674-4E55-9C29-C52E2F468AE9Q38854625-E6CE8A68-5DE2-449A-9B2D-48C3569C77FFQ38948260-ADF29375-B94E-4264-9167-8A41848EBB58Q39013686-1E231F19-BA4B-4C41-A109-1FB35F2BA2E2Q39405521-47E9D8A2-549D-41FC-96DC-BFE0277726C9Q39427565-4CC5C6C3-0EE4-4016-8FD5-A81131F3576FQ39542027-E0A397A2-975C-4574-B8B4-7DA3726AD7D8Q39776032-9C5753EA-6085-4897-A279-2ACBA0ABD562Q39788723-2BB7AEBF-98D7-44AB-84C2-877379177CCBQ39796367-A394C679-0D4B-4F15-84FD-FB3BD98A6C3BQ40087770-70D51C6B-BB72-4B8E-9792-38905DC0E5EDQ40182196-5FFB3A7C-FF99-42AA-8389-F9485DEB04D6Q40208131-78F95DC1-0505-4AD7-BA0E-B144BFEA1498Q41932925-C7F81BEA-286E-44D5-9501-552B8B20ABAFQ41970339-3184DD2B-6A5F-4EFA-87C6-F11E525D5112
P2860
Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Vesicular stomatitis virus: a ...... ent of hematologic malignancy.
@en
type
label
Vesicular stomatitis virus: a ...... ent of hematologic malignancy.
@en
prefLabel
Vesicular stomatitis virus: a ...... ent of hematologic malignancy.
@en
P2093
P356
P1433
P1476
Vesicular stomatitis virus: a ...... ent of hematologic malignancy.
@en
P2093
Brian D Lichty
David F Stojdl
Harold Atkins
Irina Frenkel
Leigh Miller
Rebecca A Taylor
P304
P356
10.1089/HUM.2004.15.821
P50
P577
2004-09-01T00:00:00Z